Seed-stage investors are pouring capital into startups at the intersection of AI and biosecurity, with Valthos and Red Queen Bio securing $45 million in recent funding rounds. Valthos raised $30 million last fall to develop AI systems that identify biological threats and design countermeasures, with backers including OpenAI, Founders Fund, and Lux Capital.

Weeks later, Red Queen Bio secured $15 million in a seed round led by OpenAI, joined by Cerberus Ventures and Fifty Years. The company's thesis centers on the exponential growth of biological risks as AI capabilities advance, arguing that defenses must scale at the same rate. Meanwhile, SecureBio received $1.4 million in grant funding from Coefficient Giving to prevent catastrophic pandemics.

While these sums pale compared to AI's broader funding landscape - representing less than one-tenth of a percent of OpenAI's record $110 billion financing - they signal growing investor confidence in biosecurity's commercial potential. Historically, biosecurity startups focused primarily on livestock applications, like ExoFlare tracking cattle and swine diseases. The latest crop of companies, however, targets human health threats, with Valthos warning that weaponizing biology now outpaces developing cures.